Abstract:Novel monometallic and heterobimetallic complexes of Zn (II) were synthesized. The newly designed complexes were characterized by infrared (FT‐IR), nuclear magnetic resonance (NMR), electron spray ionization mass spectrometry, powder X‐ray diffraction, molar conductivity, and UV–vis. Density functional theory calculations were performed to calculate the stability and chemical reactivity of the newly designed Zn (II) complexes. In vitro antimicrobial, anti‐inflammatory, and anticancer activities of the newly synthesized complexes were evaluated. In the present work, new heterobimetallic complexes with the general formula [Zn(C16H32N8)M2(R)4Cl2], where M = Sn (IV) and Si (IV) and R = ‐CH3 and ‐C6H5, were synthesized by reacting the methanolic solution of the monometallic complex [Zn(C16H36N8)Cl2] with group 14 organometallic dichloride [(CH3)2SnCl2/(C6H5)2SnCl2/(CH3)2SiCl2/(C6H5)2SiCl2]. The structures of the synthesized complexes were determined using several spectrometric techniques, including FT‐IR, 1H NMR, 13C NMR, 119Sn NMR, 29Si NMR, ESI‐MS, PXRD, and molar conductivity measurements. Density functional theory (DFT) calculations were carried out to investigate the quantum chemical characteristics of the newly synthesized Zn (II) complexes. The antimicrobial potential of the monometallic and heterobimetallic complexes was evaluated against two Gram‐positive bacteria (Bacillus subtilis and Bacillus cereus), two Gram‐negative bacteria (Xanthomonas campestris and Pseudomonas aeruginosa), and two fungal strains (Aspergillus flavus and Fusarium oxysporum) by the agar well diffusion method, with heterobimetallic complex [Zn(C16H32N8)Sn2(C6H5)4Cl2] as the most potent complex against microbes. The complex [Zn(C16H32N8)Sn2(C6H5)4Cl2] exhibited significant potential in inhibiting inflammation, demonstrating an IC50 value of 9.75 μg/mL, which closely rivals that of the standard drug sodium diclofenac (IC50 = 4.59 μg/mL). Furthermore, all the synthesized compounds were assessed for their anticancer potential against three cancer cell lines (HCT‐116, MCF‐7, and HeLa) by the MTT assay. The results indicated that the complex [Zn(C16H32N8)Sn2(C6H5)4Cl2] exhibited the most pronounced cytotoxic effects, with values of 4.25 ± 0.15 μM, 4.90 ± 0.18 μM, and 5.20 ± 0.24 μM observed for HCT‐116, MCF‐7, and HeLa cancer cell lines, respectively.

Synthesis, characterization, and anticancer activity of Co(II), Cu(II), and Zn(II) complexes containing mefenamic acid and 2-methylimidazole

Synthesis, crystal structures and anticancer studies of Ni (II), Co (III) and Zn (II) complexes based on 5-bromosalicylaldehyde- 2-(2-aminophenyl)benzimidazole Schiff base

Crystal Structures, Interactions with Biomacromolecules and Anticancer Activities of Mn(II), Ni(II), Cu(II) Complexes of Demethylcantharate and 2-Aminopyridine

Syntheses, Crystal Structures and Antitumor Activity of Ni((II)/Zn(II) Complexes Containing Cephalexin Hydrolysate

Synthesis, structure and anticancer studies of Cu (II), Ni (II) and Co (II) complexes based on 2,3-dihydroxybenzaldehyde-2-(2-aminophenyl)benzimidazole Schiff base

Synthesis of New Naphthyl Aceto Hydrazone-Based Metal Complexes: Micellar Interactions, DNA Binding, Antimicrobial, and Cancer Inhibition Studies

The non-steroidal anti-inflammatory drugs based on Zinc(II) picoline complexes: Synthesis, characterization, and evaluation of antiproliferative effects against human breast adenocarcinoma MDA-MB-453 cells by inducing ROS-mediated apoptosis and down-regulating PI3K/AKT signaling pathway

Innovation of some novel complexes based on 1‐(4‐nitrophenyl)‐1H‐1,2,3‐triazol‐4‐yl)methanol ligand: Synthesis, structural elucidation DFT calculation and pharmaceutical studies

Exploration on Synthesis, Characterization and Biological Activities of Transition Metal Complexes Comprising Hydroxybenzylideneaminocyclohexylimino-methyl-4,6-dibromophenol Schiff Base Ligand

Insighting the Inhibitory Potential of Metal Complexes Supported by ( E )-2-Morpholino- N -(thiophen-2-ylmethylene)ethanamine: Synthesis, Structural Properties, Biological Evaluation and Docking Studies

Synthesis and Investigations of the Antitumor Effects of First-Row Transition Metal(II) Complexes Supported by Two Fluorinated and Non-Fluorinated β-Diketonates

Synthesis and Structure Elucidation of Two Essential Metal Complexes: In-Vitro Studies of Their BSA/HSA-Binding Properties, Docking Simulations, and Anticancer Activities

Silver(I) Complexes with Mefenamic Acid and Nitrogen Heterocyclic Ligands: Synthesis, Characterization, and Biological Evaluation

Preparation, Characterization, DFT Calculations, Antibacterial and Molecular Docking Study of Co(II), Cu(II), and Zn(II) Mixed Ligand Complexes

Antiproliferative activity of Fe(II), Co(II), Ni(II), Cu(II), and Zn(II) complexes of dithiocarbamate: synthesis, structural characterization, and thermal studies

Synthesis, Structural Elucidation, Density Functional Theory Calculations, In Vitro Antimicrobial, Anti‐Inflammatory and Anticancer Activities of Novel Zn (II)‐Group Fourteen Heterobimetallic Complexes Derived From Schiff Base Ligand

New Ligand-Based Metal Complexes: Synthesis, Spectroscopic Characterization, Thermal Behavior, Anticancer Properties, and Biological Activity

Physico-Chemical Study of Mn(II), Co(II), Cu(II), Cr(III), and Pd(II) Complexes with Schiff-Base and Aminopyrimidyl Derivatives and Anti-Cancer, Antioxidant, Antimicrobial Applications

Synthesis, X-ray Structure and Biological Studies of New Self-Assembled Cu(II) Complexes Derived from s-triazine Schiff Base Ligand

Synthesis, characterization, biological potency, and molecular docking of Co2+, Ni2+ and Cu2+ complexes of a benzoyl isothiocyanate based ligand

Synthesis, structure, electrochemistry, and spectral characterization of bis-isatin thiocarbohydrazone metal complexes and their antitumor activity against ehrlich ascites carcinoma in swiss albino mice